SOLV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the data provided, Solventum Corp (SOLV) is not a strong buy for a beginner investor with a long-term strategy at this moment. The technical indicators are bearish, and there are no strong proprietary trading signals or significant positive catalysts to justify immediate entry. While the company has shown some positive financial performance and analyst upgrades, the current market sentiment and price trend suggest waiting for a better entry point.
The technical indicators for SOLV are bearish. The MACD histogram is negative and expanding downward, the RSI is at 26.91 (neutral zone but close to oversold), and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level (S1: 69.777), with resistance levels at R1: 76.592 and R2: 78.697.
Analysts have recently upgraded the stock and raised price targets, with KeyBanc and Mizuho providing optimistic outlooks.
The company announced a $1 billion share repurchase program starting in January 2026, which could support the stock price in the long term.
Net income and EPS showed significant YoY growth in Q4 2025.
The stock has declined despite strong Q4 earnings, indicating weak investor sentiment.
Gross margin dropped by 4.69% YoY, and revenue showed a slight decline of -3.71% YoY.
Technical indicators and recent price trends are bearish, with no clear reversal signals.
Options data shows a higher put volume compared to call volume, suggesting bearish sentiment.
In Q4 2025, Solventum reported revenue of $1.998 billion, down -3.71% YoY. However, net income increased significantly by 103.23% YoY to $63 million, and EPS doubled to 0.36. Gross margin declined to 51.4%, down -4.69% YoY. The company also announced a $1 billion share repurchase program starting in January 2026.
Analysts have shown a positive trend in ratings and price targets. KeyBanc upgraded the stock to Overweight with a $97 price target, and Mizuho raised its target to $100, citing strong growth potential and an encouraging start after the spinoff from 3M. UBS also raised its price target to $82. However, the stock remains Neutral-rated by some analysts, reflecting mixed sentiment.
